ASH
13 grudnia 2021
63rd American Society of Hematology (ASH) Annual Meeting u0026 Exposition, December 11 – 14, 2021
2021
RVU120 (CDK8/CDK19), daposertib (MEN1703 / SEL24), PIM/FLT3
Zasoby na tej stronie
Pobierz zasoby
- plik pdf
"CLI120-001 Phase Ib Study of RVU120 (SEL120) in Patients with AML and High-Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation"
Pobierz - plik pdf
"RVU120 – a CDK8/19 Inhibitor for the Treatment of AML and HR-MDS Can Induce Erythroid Differentiation"
Pobierz - plik pdf
"Inhibition of Cyclin Dependent Kinase 8 (CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)"
Pobierz - plik pdf
"Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML"
Pobierz - plik pdf
"SEL24(MEN1703) Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial"
Pobierz